Wealth Alliance LLC Has $1.63 Million Stock Holdings in Sanofi $SNY

Wealth Alliance LLC increased its stake in Sanofi (NASDAQ:SNY) by 4.3% in the 2nd quarter, Holdings Channel reports. The firm owned 33,713 shares of the company’s stock after purchasing an additional 1,400 shares during the period. Wealth Alliance LLC’s holdings in Sanofi were worth $1,629,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Accent Capital Management LLC acquired a new position in shares of Sanofi in the 1st quarter worth approximately $29,000. Eastern Bank lifted its position in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares during the period. Ameritas Advisory Services LLC acquired a new position in shares of Sanofi in the 2nd quarter valued at $28,000. Banque Transatlantique SA acquired a new position in Sanofi in the first quarter valued at about $33,000. Finally, Brentview Investment Management LLC acquired a new stake in shares of Sanofi in the 1st quarter valued at approximately $42,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY stock opened at $51.69 on Wednesday. The company has a market capitalization of $126.93 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 1.38 and a beta of 0.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.94 and a current ratio of 1.06. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a 50-day simple moving average of $48.70 and a 200 day simple moving average of $49.43.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.60 by $0.10. The company had revenue of $14.53 billion for the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm’s revenue for the quarter was down 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.25 earnings per share. On average, sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, November 5th. Finally, Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $56.00 to $58.00 in a report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Sanofi currently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.